Get Live Data

focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News
  5. Notice of Results

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,304.00
Bid: 12,302.00
Ask: 12,306.00
Change: -60.00 (-0.49%)
Spread: 4.00 (0.033%)
Open: 12,358.00
High: 12,376.00
Low: 12,276.00
Prev. Close: 12,364.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

3 Feb 2016 09:00

RNS Number : 8527N
AstraZeneca PLC
03 February 2016
 

 

 

AstraZeneca PLC Full-Year and Q4 Results 2015

 

On Thursday, 4 February 2016, AstraZeneca PLC will release its full-year and Q4 2015 results at 07:00 GMT.

 

A presentation will take place at 12:00 GMT (07:00 EST, 13:00 CET) and will be accessible via two routes:

 

Audio webcast

 

The slides will be available to download via http://www.astrazeneca.com/investors prior to the start of the presentation.

 

Teleconference

 

UK (freephone): 0800 376 922

US (toll-free): 1 866 966 1396

Sweden (freephone): 0207 92102

International: +44 20 7192 8000

Conference ID: 22241252

 

Details of the teleconference and webcast replay facilities are available via http://www.astrazeneca.com/investors.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORAKBDDABKDPBK
789101112131415
Date   Source Headline
2nd Jan 20203:00 pmRNSTotal Voting Rights
30th Dec 20197:00 amRNSUS FDA approved Lynparza for pancreatic cancer
23rd Dec 20197:00 amRNSTriple-combination approved in China for COPD
23rd Dec 20197:00 amRNSEnhertu (trastuzumab deruxtecan) approved in US
20th Dec 20197:00 amRNSAstraZeneca divests rights to Arimidex and Casodex
17th Dec 20196:06 pmRNSFDA panel backs Lynparza use for pancreatic cancer
16th Dec 20197:00 amRNSSeroquel rights agreement complete: Europe, Russia
12th Dec 20197:00 amRNSImfinzi approved in China for Stage III NSCLC
11th Dec 20191:00 pmRNSTrastuzumab deruxtecan achieves ORR of 60.9%
5th Dec 20197:00 amRNSLynparza approved in China for 1L BRCAm ovarian
3rd Dec 20197:00 amRNSAstraZeneca divests Seroquel rights: US and Canada
2nd Dec 20193:00 pmRNSBlock listing Interim Review
2nd Dec 20193:00 pmRNSTotal Voting Rights
29th Nov 20197:00 amRNSImfinzi granted FDA Priority Review for SCLC
21st Nov 20196:15 pmRNSCalquence approved in CLL in the US
15th Nov 20197:00 amRNSQtrilmet approved in the EU for treatment of T2D
14th Nov 20197:00 amRNSFDA accepts regulatory submission for selumetinib
12th Nov 20197:00 amRNSAnifrolumab demonstrated superiority in TULIP 2
11th Nov 20197:00 amRNSRoxadustat pooled analyses: no increased CV risk
8th Nov 20197:00 amRNSRoxadustat significantly increased haemoglobin
6th Nov 20192:10 pmRNSCalquence data to show improved progression-free
1st Nov 20193:00 pmRNSTotal Voting Rights
30th Oct 20197:00 amRNSAstraZeneca divests rights to Seroquel and
28th Oct 20193:31 pmRNSImfinzi and Imfinzi plus tremelimumab delayed
24th Oct 20197:00 amRNSAstraZeneca year-to-date and Q3 2019 results
21st Oct 20197:00 amRNSFarxiga approved in the US to reduce the risk of
17th Oct 20197:00 amRNSTrastuzumab deruxtecan granted FDA Priority Review
4th Oct 20193:04 pmRNSHolding(s) in Company
4th Oct 20193:00 pmRNSHolding(s) in Company
4th Oct 20197:00 amRNSFasenra approved in the US for self-administration
3rd Oct 20194:00 pmRNSDirector Declaration
1st Oct 20193:00 pmRNSTotal Voting Rights
1st Oct 20197:05 amRNSAstraZeneca divests rights for Losec to Cheplaphar
1st Oct 20197:00 amRNSUpdate on US regulatory review of PT010 in COPD
30th Sep 20193:30 pmRNSLynparza more than doubled the time without
30th Sep 20197:00 amRNSTagrisso is the only 1st-line treatment for EGFR-
30th Sep 20197:00 amRNSLynparza improved the time women lived without
23rd Sep 20197:00 amRNSQtrilmet recommended for approval in EU by CHMP
18th Sep 20197:00 amRNSAstraZeneca amends collaboration with Ironwood
9th Sep 20198:38 amRNSImfinzi is first immunotherapy to show both
4th Sep 20197:11 amRNSTagrisso approved in China as a 1st-line treatment
2nd Sep 20193:00 pmRNSTotal Voting Rights
2nd Sep 20197:05 amRNSBrilinta reduced the risk of cardiovascular events
2nd Sep 20197:00 amRNSDetailed results from Phase III DAPA-HF trial
29th Aug 20197:00 amRNSAnifrolumab Phase III trial meets primary endpoint
28th Aug 20197:05 amRNSFasenra granted US Orphan Drug Designation for
28th Aug 20197:00 amRNSBreztri Aerosphere Phase III ETHOS trial met
22nd Aug 20197:00 amRNSRoxadustat approved in China for the treatment of
22nd Aug 20197:00 amRNSAstraZeneca agrees to buy US FDA Priority Review
21st Aug 20197:00 amRNSUpdate on the Phase III NEPTUNE trial
789101112131415

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.